NB
Last reporting period 30 Jun, 2024
Updated 19 Sep, 2024
Last price
—
Market cap $B
12.35
Exchange
XNAS - Nasdaq
1 B
Last period Cash and equivalents ,USD
68%
Cash and equivalents has increased in 5 years
What is Cash and equivalents ?
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
See also Neurocrine
Company Analysis
NBIX valuation, rating, competitors, insights and company profile
Eyestock Rating
NBIX financial analysis by Eyestock methodology
Valuation
NBIX valuation using historical relative method
Statements
NBIX Income Statements, Balance Sheet and Cash Flow Statements
Dividends
NBIX dividend yield and annual dividend
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
Neurocrine`s Cash and equivalents for the period ended 2024-06-30 are 1 B USD
